Literature DB >> 12641483

Prevalence and implications of uncontrolled systolic hypertension.

William B Kannel1.   

Abstract

Risk of cardiovascular disease (CVD) increases incrementally with blood pressure, even within the high-normal range. In the general population, 27% of CVD in women and 37% in men is attributable to hypertension. A high percentage of these hypertension-related events occur in those with high-normal blood pressure and mild hypertension; about one-fourth of CVD events in elderly women and one-third in elderly men in the Framingham Study occurred in persons who had blood pressures of 140-159 mm Hg systolic and/or 90-95 mm Hg diastolic. The average systolic blood pressure (SBP) at which coronary heart disease occurs is rather modest (141 mm Hg), as is the pulse pressure (59-63 mm Hg). Of the CVD events in elderly participants in the Framingham Study, 24% in men and 36% in women occurred in persons receiving treatment for hypertension. There is a growing recognition of the importance of the systolic component of blood pressure. About 65% of hypertension in the elderly is isolated systolic hypertension (ISH), and CVD risk increases with pulse pressure. Pulse pressure is not simply a marker for stiff diseased arteries; treatment of ISH in trials promptly reduces the CVD risk, indicating that the pulse pressure generated by the stiff artery is the culprit. Analysis of data from clinical trials indicates that greater reliance should be placed on systolic pressure in evaluating the CVD potential of hypertension. Hypertension, including ISH, seldom occurs in isolation from other risk factors and overt CVD. Risk varies widely depending on the burden of accompanying risk factors. This makes global risk assessment mandatory for evaluating risk and the urgency and nature of treatment required. Evidence incriminating systolic pressure as the dominant blood pressure determinant of CVD has not been translated into clinical practice. Most of the uncontrolled hypertension observed in the Framingham Study is concentrated in those with ISH. This also extends to African-Americans, people with diabetes mellitus and the elderly. When should SBP be considered controlled? Substantial evidence supports the value of treating ISH with SBP exceeding 160 mm Hg. Trial data are not yet available to support recommendations to treat lesser elevations of ISH or pulse pressure per se, but since one-half of patients with mild ISH have two or more additional risk factors, most are candidates for treatment. In such patients, ISH should be considered controlled when their global CVD risk is reduced to below the average for their age.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12641483     DOI: 10.2165/00002512-200320040-00004

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  31 in total

1.  1999 WHO/ISH Hypertension Guidelines--highlights & ESH update.

Authors:  Sverre E Kjeldsen; Serap Erdine; Csaba Farsang; Peter Sleight; Guiseppe Mancia
Journal:  J Hypertens       Date:  2002-01       Impact factor: 4.844

2.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

3.  Unrecognized myocardial infarction and hypertension: the Framingham Study.

Authors:  W B Kannel; A L Dannenberg; R D Abbott
Journal:  Am Heart J       Date:  1985-03       Impact factor: 4.749

4.  Perspectives on systolic hypertension. The Framingham study.

Authors:  W B Kannel; T R Dawber; D L McGee
Journal:  Circulation       Date:  1980-06       Impact factor: 29.690

5.  Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study.

Authors:  S S Franklin; S A Khan; N D Wong; M G Larson; D Levy
Journal:  Circulation       Date:  1999-07-27       Impact factor: 29.690

6.  Barriers to hypertension care and control in young urban black men.

Authors:  M N Hill; L R Bone; M T Kim; D J Miller; C R Dennison; D M Levine
Journal:  Am J Hypertens       Date:  1999-10       Impact factor: 2.689

7.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

8.  Differential control of systolic and diastolic blood pressure : factors associated with lack of blood pressure control in the community.

Authors:  D M Lloyd-Jones; J C Evans; M G Larson; C J O'Donnell; E J Roccella; D Levy
Journal:  Hypertension       Date:  2000-10       Impact factor: 10.190

Review 9.  Actual blood pressure control: are we doing things right?

Authors:  A Coca
Journal:  J Hypertens Suppl       Date:  1998-01

10.  Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension.

Authors:  Kathryn E Ferrier; Michael H Muhlmann; Jean Philippe Baguet; James D Cameron; Garry L Jennings; Anthony M Dart; Bronwyn A Kingwell
Journal:  J Am Coll Cardiol       Date:  2002-03-20       Impact factor: 24.094

View more
  14 in total

1.  Detection of hypertension in the emergency department.

Authors:  J Fleming; C Meredith; J Henry
Journal:  Emerg Med J       Date:  2005-09       Impact factor: 2.740

2.  Systolic blood pressure elevation: it's where the action is.

Authors:  Jan N Basile
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

3.  Origins of disparities in cardiovascular disease: birth weight, body mass index, and young adult systolic blood pressure in the national longitudinal study of adolescent health.

Authors:  Liana J Richardson; Jon M Hussey; Kelly L Strutz
Journal:  Ann Epidemiol       Date:  2011-04-16       Impact factor: 3.797

4.  Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study.

Authors:  Antonio Coca Payeras; Krzysztof Sladek; Giuseppe Lembo; Marco Alberici
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 5.  Use of calcium channel antagonists for the treatment of hypertension in the elderly.

Authors:  Hans-Michael Steffen
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association.

Authors:  Thomas G Pickering; Nancy Houston Miller; Gbenga Ogedegbe; Lawrence R Krakoff; Nancy T Artinian; David Goff
Journal:  Hypertension       Date:  2008-05-22       Impact factor: 10.190

Review 7.  Optimal drug treatment of systolic hypertension in the elderly.

Authors:  Giuseppe Pannarale
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 8.  Wide pulse pressure: A clinical review.

Authors:  Kevin S Tang; Edward D Medeiros; Ankur D Shah
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-28       Impact factor: 3.738

9.  Physician perception of blood pressure control and treatment behavior in high-risk hypertensive patients: a cross-sectional study.

Authors:  José R Banegas; Krista Lundelin; Mariano de la Figuera; Juan J de la Cruz; Auxiliadora Graciani; Fernando Rodríguez-Artalejo; Juan García Puig
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

Review 10.  Who should be treated with combination therapy as initial treatment for hypertension?

Authors:  George L Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Jul-Aug       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.